EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer

Satoshi Katayama, Keiichiro Mori, Benjamin Pradere, Ekaterina Laukhtina, Victor M Schuettfort, Fahad Quhal, Reza Sari Motlagh, Hadi Mostafaei, Nico C Grossmann, Pawel Rajwa, Marco Moschini, Romain Mathieu und 8 weitere

World Journal of Urology · 2021-12 · 39 (12) · 4355-4361

DOI: 10.1007/s00345-021-03740-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift World Journal of Urology, online erschienen am 18.06.2021. Verfasst von Satoshi Katayama und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC)

Methods

In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models.

Results

Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23–2.77; P = 0.003) and CSS (HR 2.53; 95% CI 1.42–4.48; P = 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57–7.31; P = 0.002) and CSS (HR 4.93; 95% CI 1.70–14.3; P = 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS.

Conclusion

Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgedFemaleHumansInflammationMaleMiddle AgedNeoplasm InvasivenessPrognosisRetrospective StudiesRisk AssessmentUrinary Bladder Neoplasms

Stichwörter der Autor:innen

BiomarkerIntermediate-riskNMIBCSIISurvival

Autor:innen und Institutionen

  • Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
  • Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
  • Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Förderung

  • Medical University of Vienna

Zitieren

APA

Katayama, S., Mori, K., Pradere, B., Laukhtina, E., Schuettfort, V. M., Quhal, F., Motlagh, R. S., Mostafaei, H., Grossmann, N. C., Rajwa, P., Moschini, M., Mathieu, R., Abufaraj, M., D'Andrea, D., Compérat, E., Haydter, M., Egawa, S., Nasu, Y., Shariat, S. F., & European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU) (2021). Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. World Journal of Urology, 39(12), 4355-4361. https://doi.org/10.1007/s00345-021-03740-3

Vancouver

Katayama S, Mori K, Pradere B, Laukhtina E, Schuettfort VM, Quhal F, et al. Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. World Journal of Urology. 2021;39(12):4355-4361. doi:10.1007/s00345-021-03740-3

BibTeX
@article{Katayama2021,
  author = {Katayama, Satoshi and Mori, Keiichiro and Pradere, Benjamin and Laukhtina, Ekaterina and Schuettfort, Victor M and Quhal, Fahad and Motlagh, Reza Sari and Mostafaei, Hadi and Grossmann, Nico C and Rajwa, Pawel and Moschini, Marco and Mathieu, Romain and Abufaraj, Mohammad and D'Andrea, David and Compérat, Eva and Haydter, Martin and Egawa, Shin and Nasu, Yasutomo and Shariat, Shahrokh F and European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU), European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)},
  title = {Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer},
  journal = {World Journal of Urology},
  year = {2021},
  volume = {39},
  number = {12},
  pages = {4355--4361},
  doi = {10.1007/s00345-021-03740-3}
}
Kostenlos starten →